International Journal of Hematology

DOI: 10.1007/s12185-019-02592-3 Pages: 1-5

Brentuximab vedotin as frontline treatment for HIV-related extracavitary primary effusion lymphoma

1. H. Lee Moffitt Cancer Center, Department of Malignant Hematology and Cellular Therapy at Memorial Healthcare System

2. Memorial Healthcare System, Department of Pharmacy

3. Memorial Healthcare System, Department of Diagnostic Radiology

4. Memorial Healthcare System, Division of Hematopathology, Department of Anatomic and Clinical Pathology

Correspondence to:
Jose D. Sandoval-Sus
Tel: (954) 265 4325
Email: jsandovalsus@mhs.net

Close

Abstract

Primary effusion lymphoma (PEL) is a rare and aggressive herpesvirus-8 (HHV-8) driven B cell non-Hodgkin’s lymphoma (NHL) that is usually associated with human immunodeficiency virus (HIV) infection, and has a poor prognosis. PEL is comprised of two clinically distinct but pathologically similar variants: classic and extracavitary PEL. Based on retrospective series, treatment options include combined antiretroviral therapy (cART) in conjunction with chemotherapy regimens used in other forms of NHLs. Treatment outcomes with this approach are usually dismal and there is no standard of care. We present a case of a patient with HIV associated CD30+ extracavitary PEL unfit for multi-agent chemotherapy, who achieved a durable complete response with single agent brentuximab-vedotin and cART.

To access the full text, please Sign in

If you have institutional access, please click here

Share the Knowledge